TACSTD2 and neoplasm: Two target antigens (ERBB2 and TROP2) were lineage-specific markers of two out of above approved ADCs—Trastuzumab deruxtecan, and Sacituzumab govitecan, which have consistently high expression across the BCa tumor population than normal samples in the TCGA-BLCA (Figure 10C).